Zimmer Biomet (ZBH) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a cha ...

Core Insights - Oak Hill Advisors (OHA) acted as the Administrative Agent and Lead Left Arranger for the private senior debt financing for Montagu Private Equity's acquisition of Tyber Medical, a prominent orthopedic device manufacturer [1][2] - The acquisition will merge Tyber Medical with Montagu's existing portfolio companies, Resolve Surgical Technologies and Intech Medical, to form a scaled contract development and manufacturing organization (CDMO) [2] - OHA's extensive experience in the CDMO sector enabled it to efficiently assess the financing opportunity [3] Company Insights - Tyber Medical specializes in orthopedic devices, providing FDA-cleared and CE-marked implants for spinal, extremity, and trauma markets, with over 50 systems released since its inception in 2012 [7] - Montagu Private Equity focuses on mid-market investments, particularly in businesses with essential products in growing markets, managing €14 billion in assets [8][9] - OHA has approximately $95 billion in assets under management across various credit strategies as of March 31, 2025, emphasizing long-term partnerships and customized credit solutions [5][6]